[go: up one dir, main page]

WO2008149244A3 - Compositions and methods comprising analogues of radicicol a - Google Patents

Compositions and methods comprising analogues of radicicol a Download PDF

Info

Publication number
WO2008149244A3
WO2008149244A3 PCT/IB2008/002497 IB2008002497W WO2008149244A3 WO 2008149244 A3 WO2008149244 A3 WO 2008149244A3 IB 2008002497 W IB2008002497 W IB 2008002497W WO 2008149244 A3 WO2008149244 A3 WO 2008149244A3
Authority
WO
WIPO (PCT)
Prior art keywords
radicicol
methods
kinase
compounds
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002497
Other languages
French (fr)
Other versions
WO2008149244A2 (en
Inventor
Nicolas Winssinger
Sofia Barluenga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/663,079 priority Critical patent/US8513440B2/en
Priority to EP08807156A priority patent/EP2173733A2/en
Publication of WO2008149244A2 publication Critical patent/WO2008149244A2/en
Publication of WO2008149244A3 publication Critical patent/WO2008149244A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are novel analogues of the natural product radicicol A of formulae I,.Ia, pi, Ha, lib and HI, pharmaceutical compositions comprising the compounds. The compounds of the invention are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase -mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase -mediated disorders and synthetic processes for the preparation of the compounds.
PCT/IB2008/002497 2007-06-05 2008-06-05 Compositions and methods comprising analogues of radicicol a Ceased WO2008149244A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/663,079 US8513440B2 (en) 2007-06-05 2008-06-05 Compositions and methods comprising analogues of radicicol A
EP08807156A EP2173733A2 (en) 2007-06-05 2008-06-05 Compositions and methods comprising analogues of radicicol a

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93317107P 2007-06-05 2007-06-05
US60/933,171 2007-06-05

Publications (2)

Publication Number Publication Date
WO2008149244A2 WO2008149244A2 (en) 2008-12-11
WO2008149244A3 true WO2008149244A3 (en) 2009-03-12

Family

ID=40094244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002497 Ceased WO2008149244A2 (en) 2007-06-05 2008-06-05 Compositions and methods comprising analogues of radicicol a

Country Status (3)

Country Link
US (1) US8513440B2 (en)
EP (1) EP2173733A2 (en)
WO (1) WO2008149244A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708143C (en) * 2007-12-07 2016-10-11 Francis G. Fang Intermediates in the synthesis of zearalenone macrolide analogs
ES2512717T3 (en) * 2009-02-27 2014-10-24 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for the treatment of retinitis pigmentosa
WO2011036299A1 (en) 2009-09-28 2011-03-31 Universite De Strasbourg Irreversible inhibitors useful for the treatment of kinase-related pathologies
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
EP3452105B1 (en) * 2016-05-06 2021-07-28 Albany Medical College Treatment of rosacea with erk kinase pathway inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016369A2 (en) * 2000-08-25 2002-02-28 Sloan-Kettering Institute For Cancer Research Novel macrocycles and uses thereof
WO2003076424A1 (en) * 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
JP2004292315A (en) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd TAK1 inhibitor
WO2006036941A2 (en) * 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016369A2 (en) * 2000-08-25 2002-02-28 Sloan-Kettering Institute For Cancer Research Novel macrocycles and uses thereof
JP2004292315A (en) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd TAK1 inhibitor
WO2003076424A1 (en) * 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
WO2006036941A2 (en) * 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors

Also Published As

Publication number Publication date
WO2008149244A2 (en) 2008-12-11
US8513440B2 (en) 2013-08-20
EP2173733A2 (en) 2010-04-14
US20100233279A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2009108383A3 (en) Substituted xanthine derivatives
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
UA105390C2 (en) Normal;heading 1;heading 2;heading 3;CHEMICAL MODIFICATION MOTIFS FOR MIRNA INHIBITORS AND MIMETICS
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
JO2892B1 (en) Inhibitors of cyp 17
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
WO2009016410A3 (en) Chemical compounds 831
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
PH12012500278A1 (en) Substituted xanthine derivatives
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2009023539A3 (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009011952A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2011023367A3 (en) Bisphosphonate-prodrugs
IN2012DN01642A (en)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008807156

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12663079

Country of ref document: US